Silent thrombosis detected by duplex in patients with lymphoproliferative disorders and its relation to anti phospholipid antibodies /
Alaa Mohammed AlSayed Mohammed
Silent thrombosis detected by duplex in patients with lymphoproliferative disorders and its relation to anti phospholipid antibodies / دراسة تجلط الدم الصامت الذى يتم اكتشافه عن طريق استخدامات الموجات الصوتيه على الأوعية الدموية فى مرضى الأضطرابات التكاثرية اللمفاوية وعلاقته بالأجسام المضادة للفوسفوليبيد Alaa Mohammed Alsayed Mohammed ; Supervised Mervat Mohamed Mattar , Sahar Nassef , Mohammed Abdelkader Mourad - Cairo : Alaa Mohammed Alsayed Mohammed , 2020 - 146 P. : charts , facimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
Rationale: Lymphoproliferative disorders consist of a heterogeneous group of disorders that are characterized by an autonomous, uncontrolled proliferation of lymphoid cells that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies reacting against phospholipids, phospholipid-protein complexes and phospholipid binding proteins, detected by different assays: lupus anticoagulant (LA), anticardiolipin (aCL) and anti-Ý2 glycoprotein I (anti-Ý2GPI) antibodies.The coincidence of malignancies and the presence of aPL has been described in many important epidemiological studies. Several studies showed that hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily increase the risk of thrombosis in these patients. Purpose: This study aims to evaluate the association of lymphoproliferative disorders and thrombosis -evident by duplex- in clinically asymptomatic patients.These results are then compared to antiphospholipid antibodies (LAC, ACL and anti- B2glycoprotein I) to detect if there is an association between thrombosis and APL. If a relation is established, APL could be used in the future as a screening tool for thrombosis risk in LPD patients. Methodology: Our study was conducted on 46 patients of lymphoproliferative disorders diagnosed by either lymph node biopsy or bone marrow aspirate and biopsy and immunophenotyping. Patients were recruited from Kasr Alainy clinical hematology department in the period from 2019 to 2020. These patients performed duplex on mesenteric and lower limb vessels to detect recent thrombosis or evidence of old thrombotic events. The patients were also investigated for PTT, LA and antibodies of B2glycoprotein I and anticardiolipin by Enzyme Linked Immune Sorbent Assay (ELISA) technique and other tests were done including CBC, liver function tests, renal function tests, LDH and coagulation profile
Anticardiolipin (aCL) Lymphoproliferative Phospholipid
Silent thrombosis detected by duplex in patients with lymphoproliferative disorders and its relation to anti phospholipid antibodies / دراسة تجلط الدم الصامت الذى يتم اكتشافه عن طريق استخدامات الموجات الصوتيه على الأوعية الدموية فى مرضى الأضطرابات التكاثرية اللمفاوية وعلاقته بالأجسام المضادة للفوسفوليبيد Alaa Mohammed Alsayed Mohammed ; Supervised Mervat Mohamed Mattar , Sahar Nassef , Mohammed Abdelkader Mourad - Cairo : Alaa Mohammed Alsayed Mohammed , 2020 - 146 P. : charts , facimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
Rationale: Lymphoproliferative disorders consist of a heterogeneous group of disorders that are characterized by an autonomous, uncontrolled proliferation of lymphoid cells that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies reacting against phospholipids, phospholipid-protein complexes and phospholipid binding proteins, detected by different assays: lupus anticoagulant (LA), anticardiolipin (aCL) and anti-Ý2 glycoprotein I (anti-Ý2GPI) antibodies.The coincidence of malignancies and the presence of aPL has been described in many important epidemiological studies. Several studies showed that hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily increase the risk of thrombosis in these patients. Purpose: This study aims to evaluate the association of lymphoproliferative disorders and thrombosis -evident by duplex- in clinically asymptomatic patients.These results are then compared to antiphospholipid antibodies (LAC, ACL and anti- B2glycoprotein I) to detect if there is an association between thrombosis and APL. If a relation is established, APL could be used in the future as a screening tool for thrombosis risk in LPD patients. Methodology: Our study was conducted on 46 patients of lymphoproliferative disorders diagnosed by either lymph node biopsy or bone marrow aspirate and biopsy and immunophenotyping. Patients were recruited from Kasr Alainy clinical hematology department in the period from 2019 to 2020. These patients performed duplex on mesenteric and lower limb vessels to detect recent thrombosis or evidence of old thrombotic events. The patients were also investigated for PTT, LA and antibodies of B2glycoprotein I and anticardiolipin by Enzyme Linked Immune Sorbent Assay (ELISA) technique and other tests were done including CBC, liver function tests, renal function tests, LDH and coagulation profile
Anticardiolipin (aCL) Lymphoproliferative Phospholipid